3 results
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
- Primary objective is to assess the local tolerability of dry powder hydroxychloroquine via the Cyclops* at different dosages.- Secondary objective is to investigate systemic pharmacokinetic parameters of dry powder hydroxychloroquine via the…
The main objective is to determine the efficacy of Lyumjev in the Inreda AP system. Secondary objectives are: to assess safety, differences in pharmacodynamics and differences in AP-related outcome measures.